Compare ADMA Biologics Inc (ADMA) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Tyson Foods, Inc. — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Tyson Foods, Inc. trades at $58.65 (market cap $20.71B). The key difference: Tyson Foods, Inc. is far larger — about 9.7× ADMA Biologics Inc's market cap, and Tyson Foods, Inc. pays a 3.47% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TSN | |
|---|---|---|
Market Cap | $2.13B | $20.71B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $68.75 |
52-Week Low | $7.60 | $50.72 |
Enterprise Value | $2.20B | $28.30B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Tyson Foods (TSN) trades at $58.82, down 0.12% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results pending. Revenue for 2025 was $54.44 billion, with a net income margin of 0.81%. Recent news highlights innovation in prepared foods and new product launches, while analyst consensus is a Buy with a $69.75 price target.
The outlook for TSN is cautiously optimistic, supported by analyst bullishness and strategic growth in value-added products. Key opportunities include strong free cash flow guidance and debt reduction. Risks involve volatile cattle prices, inflationary pressures, and competitive market dynamics. The stock presents a potential upside from current levels, contingent on execution of long-term growth strategies and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
